TCG Lifesciences ties up with US based Constella Group

Kolkata, Jul 23(UNI) TCG Lifesciences, an India-based contract drug discovery&development company, today announced that it has entered into a partnership with Constella Group, a leading global provider of professional health services.

As part of the non-exclusive relationship, TCG Lifesciences and Constella would jointly promote their contract services, identify and promote business opportunities across the two organisations.

Working with TCG Lifesciences' clinical research and development arm(ClinInvent), Constella would expand its clinical trial services into India.

Constella would promote ClinInvent's clinical services to its clients interested in conducting clinical trials studies in India.

In return, TCG Lifesciences would promote Constella's services in Europe and the United States.

Constella and TCG Lifesciences would work together to explore market opportunities in India for training, quality assurance, and regulatory affairs services.

TCG Lifesciences Managing Director Swapan Bhattacharya said, ''We are confident that the alliance with Constella Group will allow us to further leverage our management team, significant experience in conducting clinical research&data management in India and access to clinicians across the country.'' Constella's Chairman and CEO Don Holzworth said, ''India is attractive to pharmaceutical and biotechnology companies because of the rapid patient recruitment into clinical studies and the country's highly skilled workforce. This partnership allows us to expand our services into new destinations.'' The partnership with TCG Lifesciences expands Constella's reach into India. The company has a corporate office in New Delhi with more than 40 employees.

UNI